Skip to main content

Bender Jeremy's Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed Feb 20, 2024

Accession no.
0001415889-24-004452
Filed
Feb 20, 2024
Trade date
Feb 15-16, 2024
Filing delay
5 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $116.1K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bender JeremyCIK 0001863107Director, Officer (CHIEF EXECUTIVE OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 15, 2024Common StockMOption exerciseAcquired+3,562–F1–712,991Direct
Feb 15, 2024Common StockMOption exerciseAcquired+4,750–F1–717,741Direct
Feb 15, 2024Common StockMOption exerciseAcquired+11,687–F1–729,428Direct
Feb 16, 2024Common StockSSaleDisposed−7,615$15.25−$116,128.75721,813Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 15, 2024Common StockMOption exerciseDisposed−3,562$0.00$024,942Direct
Feb 15, 2024Common StockMOption exerciseDisposed−4,750$0.00$052,250Direct
Feb 15, 2024Common StockMOption exerciseDisposed−11,687$0.00$0175,313Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.

Referenced by the price of 3 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)